Clinical trialNCT03058289CompletedPhase 1/PHASE2Interventional

A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6

SponsorIntensity Therapeutics, Inc.Enrollment111Bile Duct CancerBreast CancerChordoma of SacrumColon CancerHead and Neck CancerLiver Cancer+5 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study evaluated the intratumoral administration of escalating doses of a novel, experimental drug, INT230-6. The study was conducted in patients with several types of refractory cancers including those at the surface of the skin (breast, squamous cell, head and neck) and tumors within the body such (pancreatic, colon, liver, lung, etc.). Sponsor also tested INT230-6 in combination with anti-PD-1 and anti-CTLA-4 antibodies.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Anthony El-Khoueiry, M.D.
USC Norris and HOAG sites
Principal Investigator
clinicaltrials.gov ↗
Anthony J. Olszanski, M.D., RPh
Fox Chase Cancer Center
Principal Investigator
clinicaltrials.gov ↗
Brian Schwartz, M.D.
Intensity Therapeutics
Study Director
clinicaltrials.gov ↗
Giles F Whalen, M.D.
UMASS Memorial Medical Group
Principal Investigator
clinicaltrials.gov ↗
Lillian Siu, M.D., FRCP
Princess Margaret Hospital, Canada
Study Chair
clinicaltrials.gov ↗
Luis Camacho, M.D.
Center for Oncology and Blood Disorders
Principal Investigator
clinicaltrials.gov ↗
Matthew Ingham, M.D.
Columbia University
Principal Investigator
clinicaltrials.gov ↗
Nilofer Azad, M.D.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

Princess Margaret Cancer Center - University Health Network
Toronto, Ontario, Canada

United States

Usc Norris
Los Angeles, California, United States
Usc Hoag
Newport Beach, California, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States
Umass Memorial Medical Center
Worcester, Massachusetts, United States
Columbia University Medical Center
New York, New York, United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
Center for Oncology and Blood Disorders
Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

INT230-6Anti-CTLA-4 antibodyAnti-PD-1 antibody

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 9 Feb 2017
Primary completion: 22 Feb 2023
Completion: 22 Feb 2023
Last update posted: 27 Feb 2025
Registered enrollment: 111
Registry id: NCT03058289

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.